MASLD Treatment: 6 Updated Practice Considerations
An evidence synthesis on resmetirom, GLP-1 receptor agonists, and noninvasive fibrosis staging for internal medicine clinicians
One-Minute Takeaway on MASLD Treatment
One-Minute Takeaway
- MASLD treatment now includes resmetirom, the first FDA-approved oral therapy for biopsy-confirmed MASH with significant fibrosis (F2–F3) based on the MAESTRO-NASH Phase 3 trial.
- GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide) demonstrate steatohepatitis resolution and emerging fibrosis benefit in adults with cardiometabolic comorbidities.
- Noninvasive risk stratification using FIB-4 followed by vibration-controlled transient elastography (FibroScan) reliably identifies advanced fibrosis without biopsy in most patients.
- Cardiovascular disease remains the leading cause of mortality in MASLD; aggressive cardiometabolic risk reduction is foundational to every management plan.
- Major evidence gaps include long-term hepatic outcome data for newer agents, head-to-head comparisons, and treatment of cirrhosis-stage disease.
Why MASLD Treatment Matters Now
Metabolic dysfunction-associated steatotic liver disease (MASLD), the renamed entity formerly called nonalcoholic fatty liver disease, affects roughly one in three adults globally. For decades, MASLD treatment relied on lifestyle change alone, with no liver-specific pharmacotherapy approved for the progressive form, metabolic dysfunction-associated steatohepatitis (MASH).
That landscape shifted decisively in March 2024, when resmetirom became the first FDA-approved drug for MASH with significant fibrosis. Phase 3 GLP-1 receptor agonist data have followed in rapid succession, and noninvasive staging tools have matured into validated risk-stratification pathways endorsed by major hepatology societies.
For internists, MASLD treatment is no longer a topic to defer to hepatology referral. Identifying patients with significant fibrosis — who carry the bulk of liver-related and cardiovascular mortality — now requires routine risk stratification using simple, accessible tools.
The clinical question this review addresses: how should internal medicine clinicians integrate noninvasive fibrosis staging, resmetirom, and GLP-1-class therapies into MASLD treatment for adults with cardiometabolic comorbidities?
What Evidence Was Reviewed
This synthesis draws on Phase 3 randomized trials of resmetirom, semaglutide, and tirzepatide; meta-analyses of noninvasive fibrosis tests; the AASLD 2023 practice guidance; the EASL-EASD-EASO 2024 clinical practice guidelines; and large cohort studies linking fibrosis stage to outcomes.
Studies were prioritized by design (RCT before prospective cohort before retrospective), sample size, and outcome relevance to general internal medicine practice. Where pivotal trials remain unreplicated, the certainty of conclusions has been graded accordingly.
| Study / Source | Design | n | Key Finding Relevant to MASLD Treatment |
|---|---|---|---|
| MAESTRO-NASH (Harrison 2024) | Phase 3 RCT, biopsy-controlled, 52-week | 966 | Resmetirom 80 mg and 100 mg met dual primary endpoint of MASH resolution and fibrosis improvement |
| ESSENCE Phase 3 (Sanyal 2025) | Phase 3 RCT, 72-week | 800 | Semaglutide 2.4 mg achieved MASH resolution and fibrosis improvement vs placebo |
| SYNERGY-NASH (Loomba 2024) | Phase 2 RCT, 52-week | 190 | Tirzepatide produced dose-dependent MASH resolution at 5, 10, and 15 mg |
| LEAN (Armstrong 2016) | Phase 2 RCT, 48-week | 52 | Liraglutide 1.8 mg produced higher MASH resolution than placebo |
| Mózes 2022 IPD meta-analysis | Individual patient data meta-analysis | 12,604 | Sequential FIB-4 then VCTE pathway has high negative predictive value for advanced fibrosis |
| Vilar-Gomez 2018 | International multicenter cohort, retrospective | 458 | Fibrosis stage, not steatohepatitis grade, drives all-cause and liver-related mortality |
| Simon 2021 | Nationwide population cohort, prospective | 10,568 | NAFLD/MASLD biopsy stage independently associated with overall and CV mortality |
| Vilar-Gomez 2015 | Prospective cohort, paired biopsy | 293 | Lifestyle-driven weight loss of 10% or more produced MASH resolution and fibrosis regression |
| AASLD 2023 Practice Guidance | Society practice guidance | NR | Two-step noninvasive risk stratification, lifestyle foundation, role for emerging pharmacotherapy |
| EASL-EASD-EASO 2024 CPG | Society clinical practice guideline | NR | MASLD nomenclature framework, staging algorithms, integrated cardiometabolic care |
Key Findings on MASLD Treatment
Resmetirom: The First MASH-Specific Pharmacotherapy
The MAESTRO-NASH Phase 3 trial of resmetirom — a thyroid hormone receptor-beta selective oral agonist — randomized 966 adults with biopsy-confirmed MASH and stage F1B, F2, or F3 fibrosis to placebo, 80 mg daily, or 100 mg daily for 52 weeks. Both active doses met the dual primary endpoint of MASH resolution without worsening fibrosis and at least one-stage fibrosis improvement without worsening MASH.
MASH resolution occurred in roughly 26% (80 mg) and 30% (100 mg) of treated patients versus approximately 10% with placebo. Fibrosis improvement was reported in 24% and 26% versus 14% with placebo. The drug also produced LDL cholesterol reductions of about 14–20%, reflecting on-target hepatic thyromimetic activity.
Resmetirom received FDA accelerated approval in March 2024 specifically for adults with non-cirrhotic MASH and significant fibrosis (F2–F3). Continued approval will depend on confirmatory long-term outcome data, which is the rationale for the ongoing 54-month MAESTRO-NASH outcomes phase.
Mechanism Note
Resmetirom selectively activates thyroid hormone receptor-beta in the liver, increasing hepatic mitochondrial fatty acid oxidation and reducing intrahepatic triglyceride content. The selectivity for THR-beta over THR-alpha is intended to minimize cardiac and bone effects of conventional thyromimetic activity.
GLP-1 Receptor Agonists: Cardiometabolic-Hepatic Synergy
GLP-1 and dual GLP-1/GIP receptor agonist trials in MASH provide concordant signals across multiple agents. The Phase 3 ESSENCE trial of semaglutide 2.4 mg (Sanyal 2025) reported MASH resolution in approximately 63% of treated patients versus 34% with placebo and fibrosis improvement in 37% versus 22% over 72 weeks.
The Phase 2 SYNERGY-NASH trial of tirzepatide (Loomba 2024) showed dose-dependent MASH resolution — reaching about 62% at the 15 mg dose — alongside meaningful weight loss and glycemic improvement. Earlier signals from the LEAN trial of liraglutide and the Phase 2 semaglutide trial established the class effect.
Mechanistically, GLP-1-class therapy drives MASH benefit primarily through weight loss, improved insulin sensitivity, and resolution of hepatic steatosis. The fibrosis signal is less mature but increasingly consistent across trials with longer treatment duration.
The Vilar-Gomez 2015 lifestyle cohort showed MASH resolution in roughly 90% of patients who achieved 10% or greater weight loss and fibrosis regression in around 45%. GLP-1 trial response rates appear consistent with the magnitude of weight loss observed, suggesting much of the hepatic benefit is mediated by weight reduction itself.
However, sub-analyses of GLP-1 trials show MASH resolution even in patients with more modest weight loss, indicating possible weight-independent mechanisms involving hepatic insulin signaling and inflammation. The class effect is more robust for steatohepatitis resolution than for fibrosis improvement, where evidence remains less mature.
No head-to-head trials have compared resmetirom with GLP-1 receptor agonists in MASH. Decision-making therefore rests on patient-specific cardiometabolic profile, fibrosis stage, biopsy status, comorbid weight or diabetes targets, and insurance coverage.
For a patient with biopsy-confirmed MASH F2–F3, the FDA label supports resmetirom directly. For a patient with cardiometabolic indications (type 2 diabetes, obesity, established CVD), GLP-1-class therapy already carries indication-driven cardiovascular benefit and offers hepatic improvement as a parallel gain.
Combination therapy is an active research question; current evidence does not yet support routine combined use.
Pioglitazone retains a guideline-supported role for biopsy-confirmed MASH, particularly with concurrent type 2 diabetes, based on the PIVENS trial and several smaller RCTs showing steatohepatitis resolution. Concerns remain about weight gain, fluid retention, and bone loss with long-term use.
Vitamin E 800 IU daily has Tier 2 evidence in non-diabetic adults with biopsy-confirmed MASH from the PIVENS trial. Long-term safety signals (including possible prostate cancer association) warrant individualized risk-benefit discussion.
Both remain reasonable options in carefully selected patients but are increasingly displaced by newer agents in the MASLD treatment algorithm.
Noninvasive Fibrosis Staging: FIB-4 and Elastography
FIB-4, calculated from age, AST, ALT, and platelet count, is the entry-level test for MASLD risk stratification. The Mózes 2022 individual patient data meta-analysis confirmed that a FIB-4 less than 1.30 has approximately 90% negative predictive value for advanced fibrosis in primary care populations.
Vibration-controlled transient elastography (FibroScan) measures liver stiffness in kilopascals and serves as the preferred second-line test. A liver stiffness measurement below 8 kPa makes advanced fibrosis unlikely; values above 12–15 kPa suggest advanced fibrosis or cirrhosis and warrant hepatology referral.
The AASLD 2023 guidance and the AGA Clinical Care Pathway both endorse a two-step approach: FIB-4 first, with elastography reserved for indeterminate or elevated results. This pathway has been operationalized in primary care settings with high feasibility and reproducibility.
Clinical Pearl — FIB-4 limitations: FIB-4 performs less well in adults under 35 (false elevation) and over 65 (false reassurance, age cutoff 2.0 sometimes used). It is also unreliable in acute liver injury, hemolysis, or thrombocytopenia from non-hepatic causes.
Cardiovascular Risk and Mortality Patterns
Across multiple long-term cohort studies, including Simon 2021 (n=10,568) and Vilar-Gomez 2018 (n=458), cardiovascular disease consistently emerges as the leading cause of death in MASLD — ahead of liver-related mortality except in cirrhosis-stage disease. Fibrosis stage, not steatohepatitis activity, is the strongest predictor of overall mortality.
The clinical implication is that effective MASLD treatment must include aggressive cardiometabolic risk reduction: statin therapy in eligible patients, blood pressure control, glycemic management, and smoking cessation. Statins are safe in MASLD and should not be withheld for asymptomatic transaminase elevation.
Quality & Consistency of Evidence
Evidence quality varies substantially across the components of contemporary MASLD treatment. The strongest signals come from large, biopsy-controlled Phase 3 trials; the weakest from areas where outcome data and head-to-head comparisons remain immature.
What the Evidence Does Not Show
Specific Evidence Gaps
Several clinically important questions about MASLD treatment remain unanswered by current data. The named gaps below should shape patient counseling and ongoing trial design rather than be subsumed into a generic call for “more research.”
- Long-term hard outcomes for resmetirom. The 54-month outcomes phase of MAESTRO-NASH (mortality, hepatic decompensation, cardiovascular events) is ongoing and required to convert accelerated approval to full approval.
- Head-to-head comparative effectiveness. No randomized comparison exists between resmetirom and GLP-1 receptor agonists in MASH, leaving sequencing and selection to indirect evidence.
- Combination therapy. Whether combining a thyromimetic with a GLP-1 agonist provides additive hepatic or cardiometabolic benefit is unproven.
- Compensated cirrhosis. The pivotal MASH trials excluded F4 disease; evidence for safety and efficacy in cirrhotic patients is essentially extrapolated.
- Pediatric MASLD pharmacotherapy. Adult trial findings are not directly transferable; pediatric data are limited and largely lifestyle-based.
- Discontinuation effects. The durability of histologic improvement after stopping pharmacotherapy is poorly characterized.
Practical Implications for MASLD Treatment
Based on the current evidence, the following practice considerations represent areas where the data are sufficiently consistent to inform routine internal medicine MASLD treatment workflows. They are framed as evidence-supported considerations, not directive recommendations.
Evidence supports first-line FIB-4 in adults with metabolic risk, with VCTE for indeterminate or elevated results. This pathway identifies advanced fibrosis without biopsy in most patients.
Phase 3 evidence supports resmetirom for adults with biopsy-confirmed MASH and significant fibrosis. Long-term outcome data are pending; access is typically through hepatology.
Evidence supports GLP-1 and dual GLP-1/GIP agonists for adults with MASLD plus type 2 diabetes, obesity, or established CVD, with parallel hepatic improvement as an additional gain.
Cohort evidence consistently shows cardiovascular disease is the leading cause of mortality in MASLD. Statin therapy, blood pressure control, and glycemic management should not be deferred.
Two additional considerations round out the practical framework. Lifestyle intervention with a 7–10% weight loss target remains the foundation of every MASLD treatment plan and produces histologic improvement comparable in magnitude to pharmacotherapy when sustained. Hepatology referral is appropriate for confirmed advanced fibrosis (LSM ≥ 12–15 kPa), suspected cirrhosis, or candidacy for biopsy-confirmed MASH pharmacotherapy.
Evidence Grade & Bottom Line
Overall Evidence Grade: Moderate to Strong — The evidence base for current MASLD treatment is strong for noninvasive staging and steatohepatitis resolution endpoints, and moderate for fibrosis improvement and pharmacotherapy class effects. Long-term hard outcomes data remain a significant residual gap and may modify current practice as they mature.
Bottom Line
- Resmetirom is the first FDA-approved oral pharmacotherapy for biopsy-confirmed MASH with significant fibrosis based on histologic surrogate endpoints.
- GLP-1 and dual GLP-1/GIP receptor agonists produce consistent steatohepatitis resolution and emerging fibrosis benefit and align well with cardiometabolic indications.
- A two-step pathway of FIB-4 followed by vibration-controlled transient elastography reliably identifies patients needing hepatology engagement.
- Cardiovascular disease drives most MASLD mortality, so risk reduction is inseparable from any MASLD treatment plan.
- Durable benefit, head-to-head comparisons, and outcomes in cirrhotic disease remain unresolved — current decisions should weigh these limitations.
Article Information & References
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. DOI: 10.1056/NEJMoa2309000
- Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. DOI: 10.1056/NEJMoa2413258
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. DOI: 10.1056/NEJMoa2401943
- Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. DOI: 10.1056/NEJMoa2028395
- Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. DOI: 10.1016/S0140-6736(15)00803-X
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. DOI: 10.1097/HEP.0000000000000323
- European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. DOI: 10.1016/j.jhep.2024.04.031
- Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161(5):1657-1669. DOI: 10.1053/j.gastro.2021.07.049
- Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-1112. DOI: 10.1016/j.cgh.2009.05.033
- Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006-1019. DOI: 10.1136/gutjnl-2021-324243
- Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70(7):1375-1382. DOI: 10.1136/gutjnl-2020-322786
- Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018;155(2):443-457. DOI: 10.1053/j.gastro.2018.04.034
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-378. DOI: 10.1053/j.gastro.2015.04.005
- Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. DOI: 10.1097/HEP.0000000000000004